MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..6 of 6 - per page
Order by
A new veterinary medicinal composition designed to maintain the oxygenic consumption, to restore hydric, electrolytic and energetic status, as well as the blood pH in affected mammals. More
Initial results indicate that sodium nitrite can be used as a potential cost-effective platform therapy for a wide variety of disease indications characterized broadly by constricted blood flow or hypoxia. More
Compositions and methods of use of A2 adenosine receptor (AR) agonists for treating conditions modulated by A2A and A2B ARs including myocardial ischemia, reperfusion injury, cystic fibrosis, erectile dysfunction, inflammation, restenosis and septic shock More
A novel PARG-like enzyme, ARH3, that appears to function in two important signaling pathways, serving to regulate both poly-ADP-ribose and O-acetyl-ADP-ribose levels. More
Methods and formulations for treating or preventing Vascular Cognitive Impairment (VCI) through mucosal administration of E-selectin, an inducible adhesion molecule on endothelial cells More
New methods for treating, minimizing and/or preventing inflammatory injury mediated by the activity of interleukin 2 (IL-2) on non-T cells, such as epithelial cells, expressing IL-2 receptors (IL-2R) More
Displaying 1..6 of 6 - per page
Order by

Your selection

Therapeutic target
Cardiovascular del
Cardiovascular disorder (other) del
Reperfusion injury del

Browse By

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
Pharmalicensing Jobs
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us